All In Biotech

Drug Trial Radar · NCT06094777

A Study of HY-0102 in Patients With Advanced Solid Tumors

A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Jun 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • HY-0102Drug

    Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of drug limited toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
  2. Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)Time frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  3. Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  4. Number of patients with changes in electrocariogram (ECG) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  5. Number of participants with changes in clinically significant vital sign from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.